Breaking News


A 12-week controlled evaluation of oral psoralen plus ultraviolet A for treatment of plaque-type psoriasis


A 12-week, single-center, randomized, double-blind, placebo-controlled trial compared the efficacy of oral psoralen and ultraviolet A (PUVA; n = 30) with UVA and placebo (n = 10). The Psoriasis Area and Severity Index (PASI) was used to assess disease severity. The primary endpoint was the percentage of patients attaining a 75% or greater decrease in the baseline PASI score (PASI 75) after 12 weeks. The results were analyzed by nonresponder imputation (NRI), last observation carried forward on the intent-to-treat population (LOCF/ITT) and per-protocol analysis (PP). In all the analyses, none of the control group (UVA and placebo) attained PASI 75. In the PUVA group 60, 63 and 86% of patients attained ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list